KIT and gastrointestinal stromal tumor: Preclinical testing demonstrated efficacy of combined mTOR and KIT inhibition in imatinib-resistant GIST.110 A phase I/II study of everolimus 2.5 mg daily and imatinib 600 mg daily, respectively, demonstrated an acceptable safety profile and potential efficacy with lengthened PFS after imatinib and sunitinib failure.111